Bulk Pharmaceutical API Sources for IMCIVREE

Bulk Pharmaceutical API Sources for IMCIVREE

Vendor	Vendor Homepage	Vendor Sku	API Url
AbaChemScene		CS-6399
MedChemexpress MCE		HY-19870
MuseChem		I009449
AA BLOCKS		AA01EO7V
THE BioTek		bt-242344

Bulk Active Pharmaceutical Ingredient (API) Sources for IMCIVREE

Last updated: February 20, 2026

What is IMCIVREE and What API Does It Use?

IMCIVREE (setmelanotide) is a prescription medication used for weight management in rare genetic diseases caused by deficiencies in the melanocortin 4 receptor pathway. It is a peptide-based API targeting the MC4R receptor pathway, primarily synthesized as a synthetic peptide with complex manufacturing requirements.

The active ingredient in IMCIVREE is setmelanotide. It is a peptide API, approximately 5 amino acids long, with high purity requirements suitable for injectable drugs.

API Characteristics and Manufacturing Overview

Setmelanotide is a synthetic peptide produced through solid-phase peptide synthesis (SPPS). This process involves sequential addition of amino acids to generate the peptide chain with stereochemical precision. Its production demands high-purity raw materials and stringent quality controls.

Key API specifications:

• Purity: ≥ 99%
• Endotoxin levels: ≤ 0.5 EU/mg
• Sterile, endotoxin-free, suitable for parenteral use

Global API Suppliers for Setmelanotide

The small peptide API market is niche, with limited manufacturers capable of delivering high-quality setmelanotide at commercial scale.

Supplier	Location	Capabilities	Certification	Volume Capability	Notes
CordenPharma	Germany/USA	Custom peptide synthesis, sterile manufacturing	cGMP, ISO 9001	Large-scale	Known for high-purity peptides, sterile APIs
Bachem	Switzerland	Peptide synthesis, GMP manufacturing	GMP, ISO 13485	Moderate	Focused on peptide APIs, emerging in complex peptides
Polypeptide Group	UK	Custom peptide production, GMP	GMP	Moderate to large	Specializes in therapeutic peptides
WuXi AppTec	China	Peptide synthesis, API manufacturing	cGMP	Large	Capable of integrated development and scale-up

Manufacturing Challenges for Setmelanotide API

• Peptide synthesis complexity: Short peptide chain simplifies synthesis but requires high stereochemical fidelity.
• Purity and endotoxin control: Strict specifications demand advanced purification methods, such as preparative HPLC.
• Scale-up limitations: Scaling peptide manufacturing remains cost-sensitive, particularly for clinical versus commercial supplies.
• Regulatory compliance: All suppliers must adhere to cGMP standards, with extensive documentation for FDA, EMA approval.

Supply Chain Considerations

• Raw materials: Synthesis depends on high-quality amino acids, often sourced from multiple vendors.
• Manufacturing timelines: Typically 4-6 months from order to release, depending on batch size and complexity.
• Global manufacturing hubs: Asia, Europe, and North America dominate, producing under strict regulatory standards.

Future Trends and Market Outlook

• Increased manufacturing capacity: Peptide APIs are seeing rising investments for improved scale.
• Emerging regional suppliers: China and India expand capabilities via partnerships with established peptide producers.
• Regulatory scrutiny: Stringent requirements for sterile, endotoxin-free APIs heighten the importance of APIC quality.

Key Takeaways

• IMCIVREE's API, setmelanotide, is sourced from specialized peptide manufacturers globally.
• The API's synthesis involves high-purity, GMP-compliant processes to meet strict specifications.
• Major suppliers include CordenPharma, Bachem, Polypeptide Group, and WuXi AppTec.
• Manufacturing challenges center on synthesis complexity, purity, and scale.
• Supply chain reliability depends on raw material quality, manufacturing capacity, and regulatory compliance.

FAQs

1. What defines a high-quality API for peptide drugs like setmelanotide?
High purity (≥99%), low endotoxin levels (≤0.5 EU/mg), sterile, and GMP-compliant manufacturing processes.

2. How long does it take to produce a batch of setmelanotide API?
Typically 4-6 months, depending on batch size and manufacturing complexity.

3. Are there regional differences in API sourcing for setmelanotide?
Yes, Asia (China, India) and Europe (Switzerland, UK, Germany) dominate, with variations in manufacturing scale and cost.

4. What are the primary challenges in scaling peptide APIs?
Cost of production, maintaining high purity, endotoxin control, and regulatory adherence.

5. How does API quality impact the approval of IMCIVREE?
API quality directly influences safety, efficacy, and regulatory approval; compliant manufacturing is essential.

---

References

[1] European Medicines Agency. (2022). Summary of Product Characteristics: IMCIVREE. Retrieved from https://www.ema.europa.eu/en/documents/product-information/imcivree-epar-product-information_en.pdf

[2] FDA. (2022). Orphan Drug Designation and Approval for Setmelanotide. Retrieved from https://www.fda.gov/drugs/development-resources/setmelanotide

[3] Bachem. (2023). Peptide Manufacturing Capabilities. Retrieved from https://www.bachem.com/solutions/peptide-manufacturing/

[4] Polypeptide Group. (2023). Peptide API Production Overview. Retrieved from https://www.polypeptide.com/solutions

[5] WuXi AppTec. (2022). Peptide API Manufacturing. Retrieved from https://www.wuxiapptec.com/services/peptide-synthesis